Introduction
============

Nicotinic acetylcholine receptors (nAChRs)[^3^](#FN4){ref-type="fn"} are cation-selective ligand-gated ion channels. They are prototypical members of the Cys-loop receptor family and are activated by neurotransmitters such as acetylcholine or choline. They also respond to numerous non-endogenous neuroactive molecules of which nicotine is the most well known ([@B1]). nAChRs are assembled as homo- or heteropentamers ([@B2]--[@B4]). The neuronal nAChR family comprises nine different α subunits and three different β subunits that contribute to a large array of receptor subtypes, posing specificity issues when addressing ligands to a specific receptor subtype. Combinations of different protomers in specific stoichiometries give rise to different nAChR subtypes, each displaying a characteristic pharmacological and biophysical profile.

Structural studies on the full-length Torpedo muscle type nAChR by cryo-electron microscopy provided a structure at 4 Å resolution ([@B5], [@B6]). Structural data at high resolution are available for acetylcholine-binding protein (AChBP), a water-soluble homolog of the nAChR ligand binding domain ([@B7], [@B8]), with various ligands (for an overview, see Ref. [@B1]). The monomeric mouse muscle type α1 nAChR ligand binding domain structure ([@B9]) has revealed that despite low sequence identity, AChBP protomers provide a very useful model, as they are structurally highly similar to mammalian nicotinic receptors. Recent three-dimensional structures of two different full-length prokaryotic ligand-gated ion channels ([@B10]--[@B12]) as well as that of GluCl, an invertebrate ligand-gated ion channel ([@B13]), also show high structural similarity to AChBPs. Because it is easily crystallizable, AChBP still represents the best template for the characterization of ligand binding to nAChR ligand binding domains.

Ligand binding in AChBPs and in nAChRs occurs at the interface between two adjacent protomers, with one of the subunits contributing to the principal face and the second subunit contributing to the complementary face of the ligand binding site ([@B7], [@B14]). In nAChRs, the principal face always arises from the α subunit, whereas the complementary face is contributed by either α- or non-α-subunits. Principal face residues are highly conserved among nAChRs and AChBPs, whereas the complementary face displays higher variability. Previous studies have shown that the complementary face residues are important in the modulation of ligand binding affinities ([@B15], [@B16]). Binding specificity to different nAChR subtypes is known to arise at least in part from subpockets located at the apical or basal regions of the binding site ([@B17], [@B18]). Such subpockets are accessible to relatively large ligands, but not necessarily to smaller nicotinic ligands, likely to display affinity differences when binding to nAChRs.

Nicotine is a plant alkaloid responsible for the addictive properties of tobacco. Among others, nicotine binding to brain nAChRs results in dopamine release, which is critically involved in reward mechanisms and in the reinforcing effect of the drug ([@B19]). Different mechanisms underlying nicotine addiction are complex and have been extensively reviewed (*e.g.* Ref. [@B20]). Nicotine replacement therapies constitute a clean and safer mode of delivery of this compound compared with smoking tobacco. Nicotine binds with high affinity to the α4β2 nAChRs (*K~i~* 1 n[m]{.smallcaps}), where it acts as a full agonist, as opposed to low affinity binding to the α7 receptor (*K~i~* 1600 n[m]{.smallcaps}) ([@B21]). Nicotine application provides a high level of occupancy at α4β2 nAChRs, maintaining them in a desensitized state associated with a reduced nicotinic functional activity ([@B19]). A novel treatment option in smoking cessation is the use of nAChR partial agonists. Partial agonists may have a therapeutic effect due to two critical molecular actions, which are to desensitize α4β2 nAChRs and to induce channel opening with higher affinity but with lower efficacy than a full agonist at equal receptor occupancy. This diminishes nicotine reinforcement and reduces the pleasure from smoking, thus aiding the continued adherence to therapy ([@B19]).

One of the α4β2 nAChR partial agonists used for smoking cessation is cytisine, a toxic plant alkaloid isolated from *Cytisus laburnum* ([@B22]). This natural product has been used as a lead compound in the development of varenicline ([@B23]), commercialized as Champix® or Chantix® by Pfizer. Varenicline also functions as a partial agonist at the α4β2 nAChRs, and both cytisine and varenicline display high affinities, with *K~i~* values of 0.17 and 0.06 n[m]{.smallcaps}, respectively, for this receptor subtype, whereas they bind with lower affinity to the α7 nAChR, with *K~i~* values of 4200 and 322 n[m]{.smallcaps}, respectively ([@B21], [@B23]). In smoking cessation therapies, application of these molecules provides a 1.5--3-fold increase in chances for quitting smoking compared with the use of placebos ([@B19]).

To understand the basis for subtype-selective and high affinity binding of partial agonists to nAChRs, we have structurally characterized complexes of *Aplysia californica* AChBP (AcAChBP) with the small α4β2 partial agonists cytisine and varenicline and compare these to an LsAChBP complex with the α4β2 agonist nicotine. We have complemented these structural studies with ligand binding studies to determine affinities. and we discuss the thermodynamic profiles of these compounds when binding to AcAChBP. These three ligands display differences in affinity when binding to different nAChR subtypes. They indeed bind to α4β2 receptors with higher affinity compared with the α7 subtype. We, therefore, assessed cytisine binding to wild type and mutant AcAChBPs engineered to reflect either α7 or α4β2 ligand binding sites to learn about selectivity properties for these receptors. Our data may contribute to further design efforts aiming at the generation of optimized subtype-specific (partial) agonists targeting nAChRs.

EXPERIMENTAL PROCEDURES
=======================

### 

#### Protein Expression and Purification

AcAChBP used in crystallization or in ITC assays was expressed as untagged protein in Sf21 insect cells using the baculovirus expression system and purified from growth medium as described previously ([@B24]). AcAChBP mutants were expressed in HEK293 cells for radioligand binding assays. A synthetic gene, codon optimized for expression in mammalian cells, coding for AcAChBP downstream of a preprotrypsin signal peptide, was purchased (Genscript) and was cloned into a pTT3 vector using BamHI and HindIII as restriction sites. The resulting plasmid was transfected into attached HEK293 cells, and medium harvested 4 days after transfection was processed as above for purifying wild type and mutant AcAChBP variants.

#### Crystallization

Untagged AcAChBP concentrated to 3 mg/ml was incubated on ice for 1 h with 1 m[m]{.smallcaps} ligand before vapor diffusion crystallization trials were set up. Co-crystals for the different ligands grew in similar conditions at room temperature in 0.6--1.2 [m]{.smallcaps} ammonium sulfate, 0.1 [m]{.smallcaps} MMT buffer at a pH ranging between 6.5 and 8.5. Crystals were cryoprotected in mother liquor supplemented with 25% glycerol and 1 m[m]{.smallcaps} ligand before they were flash-frozen in liquid nitrogen.

#### Structure Solution and Refinement

Data were collected on beamlines ID14-4 or on beamline PX1 at SLS (Switzerland) ([Table 1](#T1){ref-type="table"}). Cytisine and varenicline co-crystals were in spacegroup I23 and diffracted to resolutions of 2.9 and 3.2 Å, respectively ([Table 1](#T1){ref-type="table"}). Data reduction was done either using XDS and XSCALE ([@B24]--[@B26]) or using MOSFLM and SCALA ([@B27]). Molecular replacement trials were performed using PHASER ([@B28]) with PDB code [2BR7](2BR7) ([@B29]) as the search model. The cytisine and varenicline co-crystals contained one pentamer in the asymmetric unit. Iterative structure refinement was performed using either REFMAC ([@B30]) from the CCP4 suite or BUSTER ([@B31]). Non-crystallographic symmetry (NCS) restraints were maintained throughout the refinement procedure using local NCSR as implemented in REFMAC or in a local version of the PDB_REDO script ([@B32]) or using the local similarity structure restraint from BUSTER. Thanks to this use of 5-fold symmetry restraints, electron density maps are much better than usual at these resolutions. One TLS group per chain was used in refinement, and both the x-ray weight and B-factor restraint weight were optimized to reduce the *R*~work~/*R*~free~ gap during refinement. Refinement was interspersed with manual rebuilding in COOT ([@B33]). All protomer-protomer interfaces enclosed a ligand molecule that was built into the electron density only in later refinement stages. All ligand molecules were well defined in electron density. Refined structures were validated using the Molprobity server ([@B34]). The figures were generated using PyMOL. Structures have been deposited in the PDB with accession codes [4AFO](4AFO) (cytisine) and [4AFT](4AFT) (varenicline), respectively.

#### Binding Assays

Isothermal titration calorimetry experiments were performed on either a VP-ITC microcalorimeter (Microcal) or on an iTC200 system (Microcal) at 25 °C. AcAChBP used in these experiments was dialyzed in a buffer containing 20 m[m]{.smallcaps} TRIS-Cl, pH 8, and 150 m[m]{.smallcaps} NaCl. The ligands investigated were dissolved in the same buffer. For a typical experiment, 100 μ[m]{.smallcaps} concentrations of ligand were titrated into 10 μ[m]{.smallcaps} AcAChBP. Titration of ligands into buffer alone was performed to determine the change in enthalpy generated by the dilution of the ligands, and this background was subtracted from the actual ligand binding experiments. Corrected data were analyzed using manufacturer supplied software and were fitted using a non-linear least squares method with a single-site binding model.

Radioligand binding assays through either classical saturation experiments or through homologous competition were performed with AcAChBP in buffer (20 m[m]{.smallcaps} Tris, pH 7.4, 0.05% Tween) in a final assay volume of 100 μl in Optiplates (PerkinElmer Life Sciences). \[^3^H\]Cytisine concentration (PerkinElmer; specific activity, ∼40 Ci/mmol) was around the *K~d~* value for the target protein. The amount of protein (4--300 ng) was chosen such that a clear window in the homologous saturation curve was obtained with sufficient events in scintillation counting and a radioligand depletion of less than 10%. WGA-YSI SPA beads (PerkinElmer) were added at 2 mg/ml final concentration. Plates were incubated at room temperature under continuous shaking and protected from light for 1.5 h. SPA beads were allowed to settle for 3 h in the absence of light before counting. The label-bead complex was counted in a Wallac 1450 MicroBeta (PerkinElmer). All radioligand binding data were fitted to a one site homologous competitive binding model using Graphpad Prism® (Version 5, GraphPad Software, Inc., San Diego, CA). At least three independent repeats were performed for the experiments.

RESULTS AND DISCUSSION
======================

We have validated the binding of three different high affinity α4β2 ligands ([Fig. 1](#F1){ref-type="fig"}*A*) currently used as smoking cessation aids, namely (−)-nicotine, (−)-cytisine, and (*meso*)-varenicline to AcAChBP. We then proceeded with the structural characterization of complexes of AcAChBP with cytisine and varenicline refined to resolutions of 2.9 and 3.2 Å, respectively ([Table 1](#T1){ref-type="table"}). Cytisine and varenicline co-crystals grew in similar conditions in space group I23 with one pentamer in the asymmetric unit (see "Experimental Procedures") and display similar homopentameric organization as previously solved AChBP structures (for review, see Ref. [@B1]). The electron density maps for these structures were much better than expected for such resolutions thanks to the use of 5-fold non-crystallographic symmetry restraints during refinement, and we could confidently build the ligands in the binding sites ([Fig. 1](#F1){ref-type="fig"}, *B* and *C*, and [supplemental Fig. S1](http://www.jbc.org/cgi/content/full/M112.360347/DC1)). All protomer-protomer interfaces in these complexes encompassed their respective ligands ([Fig. 1](#F1){ref-type="fig"}, *B* and *C*) with the C loop closed over the ligand binding site. Tips of the C-loops from different protomers were not involved in crystal packing. All the ligands above are enclosed in the characteristic aromatic cage constituted of residues Tyr-91, Trp-145, Tyr-186, and Tyr-193 from the principal face and residue Tyr-53 from the complementary face. Hydrophobic interactions from disulfide-bonded Cys-188 and Cys-189 from loop C further stabilized the ligands in the binding site. We further compared binding modes of α4β2 partial agonists cytisine and varenicline with that of nicotine in complex with LsAChBP ([@B14]).

![*A*, shown are chemical structures of ligands used in this work: nicotine, cytisine, and varenicline. Bottom views of AcAChBP in complex with cytisine (*B*) and varenicline (*C*) are shown. Each chain of the pentameric assembly is colored differently. Two blown-up views of one protomer-protomer interface are provided for cytisine (*left*) and for varenicline (*right*), with interacting residues represented using *sticks* and placed in the δA-weighted 2m*F~o~* − d*F~c~* electron density map contoured at 1σ (*blue mesh*), carved 6.5Å around the ligands. In these blown-up views, principal face residues are in *blue*, whereas the complementary face residues are colored *orange*.](zbc0271213300001){#F1}

###### 

**Crystallographic parameters for the AcAChBP co-crystal structures with cytisine and varenicline**

                                    AcAChBP-Cytisine         AcAChBP-Varenicline
  --------------------------------- ------------------------ ------------------------
  Data collection                   ESRF ID14-4              SLS PX1
  Space group                       *I23*                    *I23*
  Cell dimensions                                            
      *a*, *b*, *c* (Å)             206.69                   207.3
      α, β, γ (°)                   90, 90, 90               90, 90, 90
  Resolution (Å)                    48.72-2.88 (3.04-2.88)   48.86-3.20 (3.37-3.20)
  *R*~merge~ (%)                    14.3 (85.9)              9.7 (90.5)
  *R*~pim~ (%)                      7.0 (42.6)               7.1 (68.3)
  *I*/σ*I*                          10.0 (1.7)               7.8 (1.1)
  Completeness (%)                  95.7 (88.7)              94.3 (97.3)
  Redundancy                        5.0 (4.9)                2.4 (2.4)
                                                             
  **Refinement**                                             
      Resolution (Å)                48.72-2.88               73.4-3.2
      No. reflections               31,313                   21,800
      *R*~work~/*R*~free~           18.5/22.4                18.8/20.8
      No. atoms                                              
          Protein                   8,213                    8,213
          Ligand/ion                82                       80
          Water                     24                       0
      *B*-factors (Å^2^)                                     
          Protein                   50.4                     101.2
          Ligand/ion                45.7                     92.0
          Water                     29.3                     −
      Root mean square deviations                            
          Bond lengths (Å)          0.011                    0.005
          Bond angles (°)           1.51                     1.06
      Poor rotamers (%)             2.23                     0.85
      Ramachandran outliers (%)     0                        0
      Ramachandran favored (%)      99.21                    98.33
      Clash score (percentile)      98th                     95th
      Overall score (percentile)    100th                    100th

### 

#### Cytisine Complex

Cytisine is a plant alkaloid that acts as a partial agonist at the α4β2 subtype nAChRs, with an EC~50~ of ∼1 μ[m]{.smallcaps} ([@B22], [@B35]). Our co-crystal structure of AcAChBP with cytisine was solved with a resolution of 2.9 Å and contains one AcAChBP pentamer per asymmetric unit. All five binding sites in the pentamer are occupied by cytisine, and the ligand adopts the same orientation in all sites ([Fig. 2](#F2){ref-type="fig"}*B*).

![Detailed views of the Ls- (*A*) or AcAChBP (*B* and *C*) binding sites are depicted. Principal face residues are colored *blue*, whereas complementary face residues are colored *orange*. Interacting residues are represented as *sticks*, and water molecules are shown as *spheres*. The nicotine-LsAChBP complex (PDB code [1UW6](1UW6)) (*A*), cytisine-AcAChBP complex (*B*), and varenicline-AcAChBP complex (*C*) are represented. *D*, shown is secondary structure matching superposition ([@B53]) of binding site principal faces of Ac-, Ls- (PDB code [1UW6](1UW6)), and BtAChBPs (PDB code [2BJ0](2BJ0), ligand omitted for clarity). Interesting, residues are represented as *blue*, *silicon*, and *orange sticks*, respectively, to outline the variability among the binding sites. For conserved residues, AcAChBP numbering is provided. *E*, shown is secondary structure matching superposition ([@B53]) of binding site principal faces of AcAChBP in complex with cytisine (*blue*) and varenicline (*orange*) and of LsAChBP in complex with nicotine (PDB code [1UW6](1UW6)). Interacting residues are represented as *sticks* to allow a comparison of binding modes for these ligands. For conserved residues, AcAChBP numbering is provided.](zbc0271213300002){#F2}

The piperidine ring of cytisine is oriented toward the basal side of the ligand binding site, whereas the pyridone ring is oriented toward the apical side. On top of the hydrophobic interactions involving the binding site aromatic cage residues (Tyr-91, Trp-145, Tyr-186, and Tyr-193), the tip of loop C (Cys-188 and Cys-189), and complementary face residues Met-114 and Ile-116, cytisine is stabilized through hydrogen bonds between the carbonyl group of Trp-145 and the pyridone ring N2 as well as between the piperidine ring N1 and the hydroxyl moiety of Tyr-91 or the Trp-145 backbone carbonyl. The cytisine oxygen is also hydrogen-bonded to a water molecule (W1) stabilized by the carbonyl backbone of Ile-104, the Ile-116 backbone amide from the complementary face, and a second water molecule (W2). This binding mode involving water molecules is highly reminiscent of nicotine binding in LsAChBP ([Fig. 2](#F2){ref-type="fig"}*A*) ([@B14]). Further hydrophobic interactions from the side chains of Val-146 from the principal face and Met-114 and Ile-116 from the complementary face also stabilize the ligand.

Ring-substituted cytisine derivatives have been generated previously to further investigate affinity and/or selectivity variations in binding to the α4β2 receptor subtype ([@B36], [@B37]). These cytisine derivatives mainly target the pyridone ring ([@B21], [@B38], [@B39]) or the piperidine ring nitrogen ([@B21], [@B38], [@B40]). Methylation of the piperidine ring nitrogen, yielding caulophylline, induces a significant loss in affinity toward the α4β2 nAChRs, likely due to steric hindrance with Tyr-91. However, interestingly a larger substitution involving a 3-ketobutyl moiety drastically increases the affinity of the cytisine derivative for the α4β2 subtype receptors, toward which it also acts as an antagonist ([@B40]). Systematic *N*-substitutions performed on the cytisine piperidine ring show that variations in affinities of cytisine derivatives result from the size of the substituent and its electron withdrawing nature ([@B41]). We have shown recently that Tyr-91 in the AcAChBP binding site can re-orient its side chain to accommodate larger ligands ([@B24]). Such a rearrangement could explain an improved binding affinity of a larger ligand for the α4β2 receptors. The Tyr-91 equivalent in the α4β2 nAChRs could indeed potentially be stabilized through hydrogen bonds to the β2 loop F Asp-168. However, given the high degree of sequence variability observed in this region in nAChRs, such stabilization of the Tyr-91 equivalent in α4β2 is hard to predict. Halogenated cytisine derivatives such as the 3-chloro- or 3-bromocytisine display higher affinity toward the α4β2 nAChRs compared with cytisine ([@B21], [@B38], [@B39]). Our AcAChBP-cytisine complex structure suggests that the presence of a chloro or bromo moiety at C(3) would increase hydrophobic interactions with the surrounding binding site residues.

Cytisine docking studies into LsAChBP ([@B42]) or into α4β2 receptors and have been performed ([@B41]). The docking trials in LsAChBP predicted an orientation that agrees well with the AcAChBP co-crystal structure ([@B42]). In contrast, the predictions based on docking of unmodified cytisine into either rat- or human α4β2-modeled nAChR binding sites indicates that the two different minimum energy poses of cytisine differ between these two species, each of which is different from our AcAChBP-cytisine co-crystal structure, with the ligand pyridone ring oriented toward the basal region of the binding sites ([@B41]). The lack of robustness of this prediction and the disparity from the nicotine binding suggests that these docking studies are likely to be incorrect.

#### Varenicline Complex

Varenicline was developed by Pfizer as medication to assist in smoking cessation using cytisine as an initial lead compound. Varenicline shows an increased affinity toward α4β2 nAChRs compared with its parent molecule and maintains a partial agonist activity ([@B23]). Our AcAChBP-varenicline complex structure refined to 3.2 Å indicates that the ligand is similarly oriented in all five protomer-protomer interfaces. The aromatic moiety of the ligand is oriented toward the apical region of the AChBP binding site, whereas the aliphatic moiety is oriented toward the basal region ([Fig. 2](#F2){ref-type="fig"}*C*). The varenicline pyrazine unit extends further toward the apical region of the AcAChBP binding site than the cytisine pyridone ring. The piperidine nitrogen occupies essentially the same position as is observed for cytisine, hence making hydrogen bonds with the phenolic hydroxyl group of Tyr-91 as well as with the Trp-145 backbone carbonyl ([Fig. 2](#F2){ref-type="fig"}*C*). Varenicline is very rigid with a planar quinoxaline moiety and does not possess any bulky decoration. The ligand is stabilized in the AcAChBP binding site through hydrophobic interactions with the aromatic cage residues as well as the vicinal disulfide-bonded Cys-188 and Cys-189. Further hydrophobic interactions arise from the side chains of Val-146 from the principal face and from the side chains of Val-106, Met-114, and Ile-116 from the complementary face. The N3 nitrogen from the pyrazine ring superposes relatively well with the nicotine pyridine nitrogen in the LsAChBP-nicotine structure ([Fig. 2](#F2){ref-type="fig"}*A*). This nitrogen in the LsAChBP-nicotine complex is involved in water-mediated interactions to the backbone carbonyls of residues Leu-102 and Met-114. Such a hydrogen bonding pattern is, however, not observed in our AcAChBP-varenicline structure probably because of low resolution. Docking trials of varenicline performed into homology-modeled α4β2 nAChR ([@B43]) orient the ligand in a similar way to what we observe in our AcAChBP-varenicline co-crystal and preserve the hydrogen-bonding pattern of the piperidine nitrogen with the α4β2 Tyr-91 and Trp-147.

#### Characterizing Ligand Binding to AChBP

We investigated the binding characteristics of nicotine, cytisine, and varenicline to AcAChBP using isothermal titration calorimetry (ITC), and we show that these three ligands bind with moderate affinities of 0.8, 1.6, and 0.3 μ[m]{.smallcaps}, respectively ([Fig. 3](#F3){ref-type="fig"}, *A--C*, [Table 2](#T2){ref-type="table"}).

![ITC titration curves for the binding of nicotine (*A*), cytisine (*B*), and varenicline (*C*) to AcAChBP are provided. Nicotine binding data were recorded on a VP-ITC instrument, whereas cytisine and varenicline binding data were recorded on an ITC200 instrument. The thermodynamic profiles for nicotine, cytisine, and varenicline binding to AcAChBP (*D*) are displayed as a *bar chart* with Gibb\'s energy (Δ*G*°) in *blue* and the enthalpic (Δ*H*°) and entropic contributions (−TΔS°) in *red* and in *green*, respectively. A similar bar chart representation is provided for the comparison of nicotine binding to Ac-, Ls-, and BtAChBPs (*E*).](zbc0271213300003){#F3}

###### 

**Binding data of cytisine, varenicline, and nicotine are reported for α4β2 and α7 nAChRs and AcAChBP as well as nicotine binding data for LsAChBP (ITC data) and BtAChBP (ITC data)**

ND, not determined.

  Protein                                  Nicotine                                   Cytisine                                   Varenicline
  ---------------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------
  α4β2 nAChR (*K~i~*) (n[m]{.smallcaps})   0.95[*^a^*](#TF2-1){ref-type="table-fn"}   0.17[*^a^*](#TF2-1){ref-type="table-fn"}   0.06[*^a^*](#TF2-1){ref-type="table-fn"}
  α7 nAChR (*K~i~*) (n[m]{.smallcaps})     6290[*^a^*](#TF2-1){ref-type="table-fn"}   4200[*^a^*](#TF2-1){ref-type="table-fn"}   322[*^a^*](#TF2-1){ref-type="table-fn"}
  AcAChBP (*K~D~*) (n[m]{.smallcaps})      835[*^b^*](#TF2-2){ref-type="table-fn"}    1640[*^b^*](#TF2-2){ref-type="table-fn"}   342[*^b^*](#TF2-2){ref-type="table-fn"}
  LsAChBP (*K~D~*) (n[m]{.smallcaps})      45[*^c^*](#TF2-3){ref-type="table-fn"}     ND                                         ND
  BtAChBP (*K~D~*) (n[m]{.smallcaps})      8[*^d^*](#TF2-4){ref-type="table-fn"}      ND                                         ND

*^a^* From Refs. [@B21] and [@B23].

*^b^* ITC data, this study.

*^c^* From Ref. [@B14].

*^d^* From Ref. [@B15].

Considering the very low binding affinity of nicotine for AcAChBP (835 n[m]{.smallcaps}) relative to Ls- (45 n[m]{.smallcaps}) or *Bulinus truncatus* (8 n[m]{.smallcaps}) AChBPs ([@B14], [@B15]), we also compared the thermodynamic profiles for nicotine binding to these different AChBPs ([Fig. 3](#F3){ref-type="fig"}*D*). Our ITC binding experiments show that differences in affinity originate mainly from differences in the enthalpic contribution rather than the entropic contribution to the binding. Notable differences arise from variability in the complementary face residues with LsAChBP residues switched from Leu-112, Met-114, and Trp-53 to Met-114, Ile-116, and Tyr-53, respectively, in AcAChBP ([Fig. 2](#F2){ref-type="fig"}, *D* and *E*). Whereas the Leu-112 and Met-114 substitutions to a methionine and an isoleucine, respectively, are conservative, the substitution of Trp-53, conserved in nAChRs, to Tyr-53 has been reported to account for a 90-fold difference in affinity of epibatidine for AcAChBP compared with LsAChBP ([@B17]). It is very likely that the drop in affinity observed in the binding of AcAChBP to nicotine stems mainly from the presence of a tyrosine rather than a tryptophan at position 53. We have previously shown that the affinity of AcAChBP for nicotine can be modulated through the Y53W mutation, increasing the observed affinity to that observed for LsAChBP ([@B24]).

Comparing the binding of nicotine, cytisine, and varenicline to AcAChBP ([Fig. 3](#F3){ref-type="fig"}*E*) shows an increase in both favorable enthalpic contribution and unfavorable entropic contribution to the binding, with an increase in the size of the ligand bound at the protomer-protomer interface. Nicotine or cytisine interaction with Ls- and AcAChBP, respectively, results in a roughly similar buried surface area of 290 Å^2^ according to analysis using the PISA web server ([@B44]), whereas binding of varenicline to AcAChBP results in a buried surface area of 300 Å^2^. Varenicline is indeed involved in hydrophobic contacts with residues that are located further at the apical side of the binding site such as Val-106 (3.6 Å), compared with cytisine (4.6 Å). On the other hand, contrary to cytisine or varenicline, nicotine does not make any hydrogen bond with Tyr-91. This probably entails a lower enthalpic contribution in the binding of nicotine but could also result in more freedom of motion for the Tyr-91 side chain, possibly lowering unfavorable entropic contribution. However, in the case of cytisine or of varenicline, the hydrogen bond between the ligand and Tyr-91 locks this residue in one conformation and potentially increases unfavorable entropic contribution to the binding of these ligands to AcAChBP.

Binding affinity can be improved by increasing favorable enthalpic and entropic contributions, for example through the growth of the ligand. In the case of varenicline, further growth toward the apical region of the binding site is likely to result in clashes with binding site residues, such as Val-106. Further growing of this molecule could, however, be achieved by extending from the varenicline piperidine moiety to explore the basal region of the binding site. Indeed, previous data show that in AcAChBP, the Tyr-91 side chain can be reoriented to accommodate large ligands by making hydrogen bonds to Tyr-53 and to Ser-165 ([@B17], [@B24]) with limited entropic penalty but with an important increase in favorable enthalpic contribution ([@B24]). Such a reorientation of the Tyr-91 side chain in nAChRs is, however, hard to predict considering that Tyr-53 is substituted by a conserved tryptophan in nAChRs and that the AcAChBP Ser-165 resides in a region displaying low sequence similarity ([Fig. 2](#F2){ref-type="fig"}*E*). The effect of such a modification to the ligand on the partial agonist nature of varenicline also remains to be investigated.

#### Correlating Binding Modes with Full or Partial Agonist Activity

In this study we included ligands acting either as a full agonist (nicotine) or as partial agonists (cytisine and varenicline) at the α4β2 nAChR subtype. AChBP does not contain a transmembrane domain, but it has previously been shown that when coupled to the transmembrane domain of the 5HT3A receptor, it can trigger low frequency opening of the ion channel upon the application of acetylcholine ([@B45]). This suggests that AChBP comprises the required structural elements to connect ligand binding to channel opening.

The degree of loop C closure in AChBPs has been formerly correlated to the binding of agonists or antagonists ([@B17], [@B18], [@B46], [@B47]). Bulky antagonist binding to AChBP results in the outward movement of loop C, whereas small molecule agonist binding leads to the C loop closing in on the binding site. Recently, the structural characterization of AChBP in complex with DMXBA, a weak α7 nAChR partial agonist, suggested that partial agonism could result from multiple binding modes in the ligand binding site ([@B48]). These different binding poses reflect both typical agonist and antagonist binding modes and correlate with different degrees of loop C closure.

Interestingly, we could not detect any significant variation in the extent of the C loop closure over the binding site when comparing the co-crystal structure of LsAChBP in complex with a full α4β2 nAChR agonist such as nicotine to those in complex with the partial agonists cytisine and varenicline ([Fig. 4](#F4){ref-type="fig"}). Indeed, in our ligand-AcAChBP structures, the C loops are further closed upon the binding site when compared with the methyllycaconitine (antagonist)-bound structure (5.7 Å) or even to the DMXBA (α7 nAChR partial agonist)-bound structure (2.7 Å). Neither cytisine nor varenicline displayed variable binding modes in AcAChBP, with the ligands adopting the same orientation in all their respective binding sites.

![**Ribbon representation of LsAChBP in complex with nicotine (*blue*), cytisine (*orange*), varenicline (*green*), methyllycaconitine (*gray*, PDB code [2BYR](2BYR)) and DMXBA (*pink*, PDB code [2WNJ](2WNJ)) superposed with respect to their principal face.** Nicotine is represented as *sticks* to indicate the orientation of a full agonist in the binding site. The tip of loop C is displaced outwards by 5.7 Å when AcAChBP is bound to the α7 nAChR antagonist methyllycaconitine and by 2.7 Å when AcAChBP is bound to partial agonist DMXBA when compared with the nicotine-bound state. No significant difference in the position of loop C is measured when AcAChBP is bound to nicotine, cytisine, or varenicline.](zbc0271213300004){#F4}

The main difference we observed between the binding modes of nicotine to LsAChBP compared with cytisine or varenicline is that both partial agonists interact with the phenolic hydroxyl group of Tyr-91 ([Fig. 2](#F2){ref-type="fig"}, *B*, *C*, and *E*). In AcAChBP Tyr-91 makes a hydrogen bond with the backbone carbonyl of Ser-144 through its hydroxyl group. This hydrogen bond is disrupted through the binding of lobeline to AcAChBP ([supplemental Fig. S2](http://www.jbc.org/cgi/content/full/M112.360347/DC1)). Lobeline, known to display a mixed agonist/antagonist mode of action toward nAChRs, is accommodated in the AcAChBP binding site through a reorientation of the Tyr-91 side chain, which makes hydrogen bonds to Tyr-53 and Ser-165 ([@B17], [@B24]). It is nevertheless unlikely that the interaction of a ligand with Tyr-91 would be sufficient to entail partial agonism. Indeed, epibatidine, which functions as a full agonist against the α4β2 nAChRs, can also make a hydrogen bond to the Tyr-91 AcAChBP hydroxyl group via its bridge ring amine ([@B17]) ([supplemental Fig. S2](http://www.jbc.org/cgi/content/full/M112.360347/DC1)).

Recently, it has been shown that varenicline acts as a potent agonist against the human 5-hydroxytryptamine 3 receptor (5HT3AR), whereas its efficacy is limited at the mouse 5HT3AR ([@B49]). This difference in efficacy was rationalized in part by docking trials performed in homology-modeled ligand binding domains of the human and mouse receptors, which suggest that varenicline adopts different binding modes in these two proteins. Differences in binding modes are attributed to differences in the human and mouse 5HT3AR loops C, which in turn lead to differences in the orientation of conserved residue side chains. One such residue, displaying differences in orientation between the human and mouse, seems to be Glu-129, which lies on an equivalent loop to the one that harbors Tyr-91 in AcAChBP. Nevertheless, whereas both the AChBP and 5HT3AR ligand binding sites contain residues making up aromatic cages, the relative positions of aromatic residues vary and are likely to be reflected in the orientation adopted by varenicline in these two binding sites.

Our structural characterization of α4β2 nAChR partial agonists in complex with AcAChBP suggest that whereas variability in the ligand binding modes is possibly one of the features that entails partial agonism to ligands, it is likely that this is not the only criterion for partial agonism. This study does not take into account the heteropentameric nature of the α4β2 nAChR, which is likely to also be critical in the definition of partial and full agonist characteristics for ligands. Further work would be required, ideally on full receptors, to better understand the mechanisms underlying partial agonism.

#### Rationalizing Binding Affinity Differences of Nicotinic Ligands to α4β2 and α7 nAChR Subtypes

Cytisine, varenicline, and nicotine are all small (162--211 gmol^−1^), high affinity binders for the α4β2 nAChRs, but all display lower affinity for the α7 subtype receptor ([Table 2](#T2){ref-type="table"}). From this initial observation, we went on to define which residues in the binding sites of these two receptor subtypes are responsible for such a large affinity difference in the binding of these molecules to these nAChRs. Our co-crystal structures with these ligands have confirmed their binding modes to AcAChBP, and together with a structure-based sequence alignment ([Fig. 5](#F5){ref-type="fig"}) ([@B50]) have allowed us to map out residues likely to be involved in binding these molecules in α4β2 or in α7 nAChR subtypes. We implemented both single and combined mutations into AcAChBP so that the binding site of the resulting protein would reflect either that of the α4β2 or of the α7 receptor subtype. The mutations ([Fig. 5](#F5){ref-type="fig"}) address residues directly in contact with the ligands in the binding site and residues previously reported to influence agonist binding to nAChRs such as G149K (AcAChBP numbering) ([@B51]). The different mutants generated were subjected to \[^3^H\]cytisine saturation or homologous competition binding assays.

![**Structure-based sequence alignment ([@B50]) of Ac-, Ls-, and BtAChBPs with the α4, β2, and α7 nAChR subunits.** Ligand binding site residues involved in nicotine binding are *boxed*. Principal face residues are colored and boxed in *blue*, whereas complementary face ligand binding residues are colored and *boxed* in *orange*. Residues that were mutated to reflect α4β2 and α7 nAChRs are indicated by a *vertical green arrow*.](zbc0271213300005){#F5}

Overall, AcAChBP mutants engineered to reflect the α7 nAChR binding site showed a lower affinity for cytisine when compared with α4β2 like mutants ([Table 3](#T3){ref-type="table"}). Indeed, combining α7 like mutations D75T or M114Q into Y53W- or Y53W/I116L-AcAChBPs resulted in affinity loss for cytisine when compared with their α4β2 counterparts ([Fig. 6](#F6){ref-type="fig"}, *A* and *B*), whereas epibatidine binding levels were not significantly altered for the same mutants. This result demonstrates that complementary face binding site residues are critical for subtype-selective ligand binding in nAChRs.

###### 

***K~D~* values obtained either from \[^3^H\]cytisine saturation (S) radioligand binding or \[^3^H\]cytisine homologous competition (HC) experiments are reported for different AcAChBP mutants**

Binding curves for these proteins to cytisine are provided in [supplemental Fig. S3 and S4](http://www.jbc.org/cgi/content/full/M112.360347/DC1).

  Mutant                  *K~D~*               Method
  ----------------------- -------------------- --------
                          *n[m]{.smallcaps}*   
  Wt                      222 ± 35             HC
  Y53W                    5.5 ± 0.5            S
  Y53W/I116L              38 ± 7               HC
  G149K                   40 ± 9               HC
  Y53W/G149K              3.9 ± 0.3            S
  Y53W/D75K               9 ± 1                S
  Y53W/M114F              21 ± 6               HC
  Y53W/I116L/G149K        10 ± 2               S
  Y53W/I116L/D75K         100 ± 15             HC
  Y53W/D75T               14 ± 2               HC
  Y53W/I116L/D75T         193 ± 17             HC
  Y53W/I116L/M114Q        200 ± 30             HC
  Y53W/I116L/V106L        56 ± 6               HC
  Y53W/I116L/D75T/M114Q   186 ± 11             HC

![***Bar charts* representing the improvement in binding affinity of selected mutants with respect to wild type AcAChBP (*A*) or to AcAChBP incorporating the Y53W mutation (*B*).** Improvement in affinity was measured as the ratio of affinities (*K~D~*) of either wild type (*A*) or Y53W (*B*) AcAChBPs to those of other AcAChBP mutants. Errors were propagated from initial radioligand binding measurements ([Table 2](#T2){ref-type="table"}).](zbc0271213300006){#F6}

Among the mutants we generated to reflect the α4β2 binding site, the Y53W/G149K AcAChBP mutant displayed the largest gain in affinity toward cytisine compared with wt-AcAChBP (57-fold) ([Fig. 6](#F6){ref-type="fig"}, *A* and *B*). Previous reports show that mutating the α7 nAChR Gly-152 to a lysine as present in α4β2 increases agonist binding affinity (102-fold toward nicotine) and increases acetylcholine potency (7-fold) ([@B51]). Similarly, mutating the α1 nAChR Gly-153 to a lysine also increased nicotine affinity for the receptor, most likely by making the binding site more accessible for agonist binding through the formation of a hydrogen bond between loops B and C ([@B52]). Such a hydrogen bond is already present in AcAChBP despite the presence of a glycine at position 149 ([Fig. 5](#F5){ref-type="fig"}), and the G149K mutation in AcAChBP does not entail a drastic affinity improvement (1.7-fold) over wt-AcAChBP. Our results indicate that mutating the AcAChBP tyrosine 53 into a tryptophan significantly enhances cytisine binding affinity, with a 40-fold decrease in the *K~D~* ([Fig. 6](#F6){ref-type="fig"}*A*), in line with previous results for other nicotinic agonists ([@B17]). We could not identify other mutations that result in improved affinity toward cytisine compared with the Y53W/G149K mutant. The M114F mutation results in a 4-fold decreased affinity for cytisine compared with Y53W-AcAChBP, probably because the side chain of the phenylalanine is forced into an unusual rotamer orientation to avoid clashes with residues Arg-57, Val-106, or Ile-116. A 7-fold decrease in affinity was also observed when comparing the Y53W/I116L mutant to Y53W, suggesting that the leucine side chain also has to adopt an unusual rotamer orientation to prevent clashes with Tyr-53, Gln-55, or Trp-145. Switching Asp-75 to a lysine in the Y53W/D75K mutant results in a 2-fold decrease in affinity compared with Y53W AcAChBP. Thus modifications in the first shell of binding site residues are not sufficient to mimic the high affinity of the α4β2 nAChRs for cytisine. This suggests that residues beyond the first shell of binding are critical for the high affinity interaction, as was previously suggested for other receptor subtypes ([@B52]).

A similar mutational approach based on structural information has been previously used to understand the difference in nicotine binding affinity between *B. truncatus* AChBP (BtAChBP) (*K~D~* = 8 n[m]{.smallcaps}) and LsAChBP (*K~D~* = 45 n[m]{.smallcaps}) ([@B15]). In this study three amino acid substitutions within the first shell of ligand binding were sufficient to improve the affinity of LsAChBP to the level of BtAChBP. The comparison between Ls- and BtAChBP structures suggested that the direct interactions with the side chains of these amino acids were critical in defining nicotine affinity ([@B15]). In this study we have extended this approach to investigate differences in affinity in the binding of cytisine to the α7 and α4β2 nAChRs. However, contrary to the previous study ([@B15]), mutating AcAChBP binding site residues to their α4β2 counterparts did not drastically improve cytisine binding affinities. This result strongly suggests that the orientation of binding site residue side chains is influenced not only by residues at the protomer-protomer interface but also by residues located outside of the ligand binding site, such as Gly-152. We believe that these residues modulate the geometry of the ligand binding site and hence the orientation of binding site residue side chains through long range interactions, entailing affinity differences during ligand binding.

We have used AChBP as a template to investigate the binding modes of three different molecules, nicotine, cytisine, and varenicline, targeted toward the α4β2 nAChR in smoking cessation therapies. The ITC data we recorded provide a rationale for differences in binding of these three ligands to AcAChBP, and our structural data provide the binding orientations of these molecules, allowing us to define binding site residues interacting with these ligands. Importantly, we find that all three ligands have similar binding poses. The detailed structures provide insight in the effect of possible chemical changes in these compounds.

Our mutational analysis of the AcAChBP binding site shows that complementary binding site residues are critical but not sufficient to entail subtype selective ligand binding to nAChRs. The decrease in affinity observed for α4β2-like mutants for cytisine suggests that complementary face residues from the binding site are probably not properly oriented for high affinity ligand binding. The orientation of residues in this primary shell of binding residues is very likely to be plastic in nature and can be influenced by longer range interactions extending farther from the ligand binding site.
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